Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : $128.0 million
Deal Type : Acquisition
Ligand to Acquire APEIRON Biologics AG for $100 Million
Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.
Product Name : Qarziba
Product Type : Antibody, Unconjugated
Upfront Cash : $100.0 million
July 08, 2024
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : $128.0 million
Deal Type : Acquisition
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Eusa Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Eusa Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AGC Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma
Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 11, 2024
Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AGC Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Renaissance Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
August 01, 2023
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Renaissance Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : United Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Rapid Administration Pilot for Infusing Dinutuximab
Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 16, 2022
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : United Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 13, 2022
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Recordati
Deal Size : $847.0 million
Deal Type : Acquisition
Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...
Product Name : Qarziba
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 03, 2021
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Recordati
Deal Size : $847.0 million
Deal Type : Acquisition
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Recordati
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leiomyosarcoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Recordati
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.
Product Name : Qarziba
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 09, 2020
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
United Therapeutics Announces Study of Unituxin® (dinutuximab)
Details : The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 03, 2020
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable